Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the FoF Domestic median (128 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 05 May 2014 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | HSBC Multi Asset Active FOF |
|---|---|
| 05 May 2014 | ₹100.00 |
| 14 May 2015 | ₹121.96 |
| 22 May 2016 | ₹126.44 |
| 01 Jun 2017 | ₹154.27 |
| 10 Jun 2018 | ₹166.70 |
| 19 Jun 2019 | ₹169.15 |
| 27 Jun 2020 | ₹161.83 |
| 06 Jul 2021 | ₹228.10 |
| 15 Jul 2022 | ₹228.09 |
| 25 Jul 2023 | ₹253.56 |
| 02 Aug 2024 | ₹294.00 |
| 11 Aug 2025 | ₹283.26 |
| 20 Aug 2026 | ₹309.13 |
| Metric | HSBC · Regular · IDCW NAV ₹30.99 Very High risk ★★☆☆☆ | Category median FoF Domestic · 128 funds |
|---|---|---|
| +7.58% | +5.71% | |
| +6.78% | +10.60% | |
| +5.81% | +7.04% | |
| +8.37% | +8.12% | |
| +9.62% | +8.44% | |
| +5.61% | — | |
| +9.49% | +9.37% | |
| +9.46% | +8.64% | |
| +9.31% | +8.30% | |
| Risk | ||
| 13.93% | 13.12% | |
| 0.02 | 0.40 | |
| 0.02 | 0.57 | |
| -25.45% | -18.33% | |
| Nifty 500 | — | |
| -2.36% | +0.09% | |
| 0.47 | 0.95 | |
| 45.8% | 92.9% | |
| 39.6% | 81.4% | |
| 1.40% | 0.58% | |
| ₹106.68Cr | ₹372.62Cr | |
| 1.00% | — | |
| None | — | |
| ₹1.00K | — | |
| ₹5.00K | — | |
| 10% | 13% | |
| Gautam Bhupal · 10.8y | — | |
| 05 May 2014 | — | |
| — | — | |
| — | — | |
| 4.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.